2-Bromo-4-butanolide

We are 2-Bromo-4-butanolide CAS:5061-21-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-Bromo-4-butanolide
CAS.NO:5061-21-2
Synonyms:α-Bromo-γ-butyrolactone
alpha-Bromo-gamma-butyrolactone
Molecular Formula:C4H5BrO2
Molecular Weight:164.98500
 
Physical and Chemical Properties:
Density:1.786;
Melting point:25oC;
Boiling point:138oC;
Flash point:109oC;
Index of Refraction:1.508;
 
Specification:
Appearance:Light yellow liquid
Purity(GC):≥98.0%
Moisture:≤0.1%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As an intermediate in organic synthesis
 

2-Bromo-4-butanolide


Related News: Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.1023674-80-7 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.N4-Isobutylquinoline-3,4-diamine CAS:99010-09-0 Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.2-Amino-4,7-dihydro-5-[2-[4-(methoxycarbonyl)phenyl]ethyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidine CAS:155405-80-4 Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”

Related Products
Product Name
5-Bromo-4-methyl-2(1H)-pyridinone View Details
5-Methyl-1,3-benzenediacetonitrile View Details
2-Bromo-5-methylpyridine View Details
2-((4-Chlorophenyl)(piperidin-4-yloxy)methyl)pyridine manufacturer Cysteamine hydrochloride manufacturer Ethylurea manufacturer 2-Fluoro-6-nitrotoluene manufacturer 1,4-Diaminobenzene Sulfate manufacturer